<DOC>
	<DOC>NCT01766063</DOC>
	<brief_summary>The study aims to investigate the relationship between sleep quality, quality of life,other disorders and therapies in Multiple Sclerosis (MS) patients treated with Betaferon.</brief_summary>
	<brief_title>Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients ≥ 18 years of age with relapsing remitting multiple sclerosis or a clinically isolated syndrome and an expanded disability status scale score ≤5. Patients must be on treatment with Betaferon and tolerate Betaferon according to the investigator's evaluation, but should not have received Betaferon longer than six months. Written informed consent must be obtained Patients who do not tolerate Betaferon according to the investigator's evaluation or have been treated with Betaferon for more than six months. Patients receiving any other disease modifying drug or MS specific treatments Contraindications of Betaferon described in the Summary of Product Characteristics.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Sleep</keyword>
	<keyword>Quality of life</keyword>
	<keyword>Observational study</keyword>
</DOC>